Accelerate to discover

Back to filter

Related topics

Top 10 Pharma companies have chosen CYTEK for their flow cytometry facility

Cytek Biosciences

Jun 21, 2021

6 of Top 10 Pharma Companies (Based on total group revenues) have chosen CYTEK - full spectrum flow cytometer for their...

Jun 21, 2021

IncuCyte webinar recording: How to measure Immune Cell Killing of Tumor Cells effectively

Sartorius

Jun 4, 2021

Immuno-oncology (IO) has transformed cancer treatment. The number of treatments in the IO pipeline continues to...

White Paper: Immunophenotyping Rare Immune Cells with Laminar Wash AUTO System

Curiox

Jun 3, 2021

The Laminar Wash (LW) AUTO system consists of a wall-less plate and a laminar flow cell washer that enable automated...

A subset of cytotoxic effector memory T cells enhances CAR T cell efficacy in a model of pancreatic

Tonbo Biosciences

Jun 3, 2021

Tonbo Biosciences flow cytometry reagents & antibodies are manufactured with the highest quality and precision and...

Jun 21, 2021

Cytek webinar : Evaluating Spectral Cytometry for Immune Profiling in Viral Disease

Cytek Biosciences

May 13, 2021

In conventional fluorescence cytometry, each fluorophore in a panel is measured in a target detector, through the use...

Show all topics (10)

Elevated NSD3 histone methylation activity drives squamous cell lung cancer

Jun 8, 2021

Amplification of chromosomal region 8p11-12 is a common genetic alteration that has been implicated in the aetiology of lung squamous cell carcinoma (LUSC)1-3. The FGFR1 gene is the main candidate driver of tumorigenesis within this region4. However, clinical trials evaluating FGFR1 inhibition as a targeted therapy have been unsuccessful5. Here we identify the histone H3 lysine 36 (H3K36) methyltransferase NSD3, the gene for which is located in the 8p11-12 amplicon, as a key regulator of LUSC tumorigenesis. In contrast to other 8p11-12 candidate LUSC drivers, increased expression of NSD3 correlated strongly with its gene amplification. Ablation of NSD3, but not of FGFR1, attenuated tumour growth and extended survival in a mouse model of LUSC. We identify an LUSC-associated variant NSD3(T1232A) that shows increased catalytic activity for dimethylation of H3K36 (H3K36me2) in vitro and in vivo. Structural dynamic analyses revealed that the T1232A substitution elicited localized mobility changes throughout the catalytic domain of NSD3 to relieve auto-inhibition and to increase accessibility of the H3 substrate.

Expression of NSD3(T1232A) in vivo accelerated tumorigenesis and decreased overall survival in mouse models of LUSC. Pathological generation of H3K36me2 by NSD3(T1232A) reprograms the chromatin landscape to promote oncogenic gene expression signatures. Furthermore, NSD3, in a manner dependent on its catalytic activity, promoted transformation in human tracheobronchial cells and growth of xenografted human LUSC cell lines with amplification of 8p11-12. Depletion of NSD3 in patient-derived xenografts from primary LUSCs containing NSD3 amplification or the NSD3(T1232A)-encoding variant attenuated neoplastic growth in mice. Finally, NSD3-regulated LUSC-derived xenografts were hypersensitive to bromodomain inhibition. Thus, our work identifies NSD3 as a principal 8p11-12 amplicon-associated oncogenic driver in LUSC, and suggests that NSD3-dependency renders LUSC therapeutically vulnerable to bromodomain inhibition.

Do you want to learn more? Read the whole article, or just ask us!

 

Scientific paper
Application

Get more info

Miroslav Vecheta

Support specialist

Miroslav

Vecheta

+420 255 700 886

Send Message

Brand profile

Spectral Instruments Imaging

Spectral Instruments Imaging manufactures instruments for preclinical optical (bioluminescent, fluorescent) and X-ray imaging.

Related products

System for individual researchers and smaller specialist teams to conduct optical imaging studies in disease model progression, response to therapy, and cell migration in-vivo.

show detail

The Ami HT and Ami HTX (includes X-Ray imaging) optical imaging systems establish a new, high throughput benchmark for in vivo imaging suitable for specialist researchers and small teams.

show detail

The Lago and X‐Ray capable Lago X optical imaging systems provide a powerful and flexible in-vivo imaging capability suitable for imaging cores, specialist researchers and small teams, delivering an unmatched 10 mouse capacity across BLI, FLI and X‐Ray.

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey